Imunon presents poster at AACR annual meeting on IMNN-001

IMUNON announces that a poster highlighting the Company’s DNA-based immunotherapy IMNN-001 was presented on April 18 at the American Association for Cancer Research, AACR, Annual Meeting in Orlando. IMNN-001 is a DNA-based interleukin-12 immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer. The poster is titled "Efficacy of IMNN-001, an Interleukin-12 Immune Gene Therapy, at Different Dose Frequencies." In the study, IMNN-001 dosing regimens were examined for efficacy in ID8 tumor-bearing mice either weekly, every two weeks or every three weeks. Six animals from each group dosed were harvested for translational research after five weekly (three every two-week and two every three-week) treatments, respectively. The remaining four animals in each group were followed for weight change and survival. Additionally, TR evaluated change in ascites T cell populations. There was a gradual rise in tumor burden and mortality in all treatment groups with comparable rates between the once weekly and once every two weeks regimen. Researchers concluded that IMNN-001 demonstrated stimulation of the immune response in the ID8 ovarian tumor model. Of the three dosing regimens tested, the once every 2-week regimen demonstrated comparability to the weekly regimen while showing superiority to the once every 3-week regimen, particularly with respect to mortality and tumor burden. Thus, exploring once every 2-week dosing of IMNN-001 in human studies is warranted.